3 Biotech Stocks That Sank: Are Any a Bad-News Buy?

Last week was an especially rough one for several small biotechs. Disappointing news for Aeglea BioTherapeutics (NASDAQ: AGLE), Bolt Biotherapeutics (NASDAQ: BOLT), and Reata Pharmaceuticals (NASDAQ: RETA) caused shares of all three companies to plunge. In this Motley Fool Live video, recorded on Dec. 8, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether any of these three biotech stocks are now bad-news buys.

Continue reading

Source Fool.com